JmdcJMDC4483東証プライム情報・通信業FY ending Mar 2026, consolidated, IFRS
About 61% of Jmdc's sales come from Healthcare-Big data, with Tele-medicine and Dispensing pharmacy support making up much of the rest.
Out of every ¥100 of sales, about ¥22 is left as operating profit.
Revenue changed +37.9% from the prior year, operating profit +66.8%.
Revenue +37.9% · profit +66.8%, calculated from disclosed figures.
Operating leverage: 1.76× (profit growth ÷ revenue growth)
FY ending Mar 2020 → FY ending Mar 2021
FY ending Mar 2020 → FY ending Mar 2021
For every ¥100 Jmdc sells, how much goes where, and how much is kept.
Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.
Revenue by business segment, and the profit each one keeps.
※ Segments without disclosed profit are drawn entirely as costs
※ Segment figures include inter-segment sales and do not sum to the company total
EDINET (FSA Japan)
有価証券報告書－第12期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第11期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第10期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第9期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
訂正有価証券報告書－第8期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 40 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.